The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …

Purpose This review provides an overview of the current challenges in oral targeted
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …

Purpose: Standard-of-care treatment for metastatic hormone receptor–positive (HR+), HER2-
negative (HER2−) breast cancer includes endocrine therapy (ET) combined with a cyclin …

Background Oral targeted therapies show a high pharmacokinetic (PK) interpatient
variability. Even though exposure has been positively correlated with efficacy for many of …

PURPOSE Oral anticancer drugs (eg, kinase inhibitors) play an important role in cancer
therapy. However, considerable challenges regarding medication safety of oral anticancer …

Renal or hepatic impairment is a common comorbidity for patients with cancer either
because of the disease itself, toxicity of previous anticancer treatments, or because of other …

Over the past 10 years, the number of targeted therapies for haematological malignancies
has substantially increased, and many new drugs have entered the market. Many of these …

Abstract Background and Objective Ruxolitinib is a tyrosine kinase inhibitor targeting the
Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways …

Palbociclib, ribociclib, and abemaciclib are inhibitors of the cyclin-dependent kinases 4 and
6 approved for the treatment of locally advanced or metastatic breast cancer. In this review …

Dabrafenib is a potent and selective inhibitor of BRAF-mutant kinase that is approved, as
monotherapy or in combination with trametinib (mitogen-activated protein kinase (MAPK) …